AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16954961 — intervention group
Group type: COMPARATOR
Intervention: Conventional casein-predominant formula (protein/energy ratio: 2.6 g/100 kcal)
Number of subjects: 162
Study 16954961 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey-predominant study formula
Number of subjects: 162
Study 16954961 — intervention group
Group type: COMPARATOR
Intervention: Conventional casein-predominant formula
Number of subjects: 162
Study 14707568 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular blocking agents (NMBA)
Number of subjects: 56
Study 14707568 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy without NMBA (Control group)
Number of subjects: 56
Study 11343407 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities with maintained action results during the activity and perceptually preserved in the end product; cue conditions: verbal, object, action, and reenactment.
Number of subjects: 0
Study 11343407 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities where action results disappeared from view during the activity and were transformed within the end product; cue conditions: verbal, object, action, and reenactment.
Number of subjects: 0
Study 11343407 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture supports provided during activities for 5‐ and 7‐year‐olds.
Number of subjects: 0
Study 8970933 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil (125, 250, 500, and 1000 microg)
Number of subjects: 1511
Study 8970933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1511
Study 8970933 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil
Number of subjects: 1511
Study 7965783 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandospirone citrate (40, 80 and 160 mg)
Number of subjects: 14
Study 7965783 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.5, 1.0 and 2.0 mg)
Number of subjects: 14
Study 7965783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2888691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracapsular extraction with contact lens fitting
Number of subjects: 327
Study 2888691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular implants after intracapsular and extracapsular extraction
Number of subjects: 327
Study 2888691 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall surgery (both treatment modes)
Number of subjects: 327
Study 31786829 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated office blood pressure measurement without preceding rest
Number of subjects: 100
Study 31786829 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated office blood pressure measurement with 5 minutes of preceding rest
Number of subjects: 100
Study 31786829 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated office blood pressure measurement without preceding rest as the first measurement
Number of subjects: 100
Study 29797670 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream (TD group)
Number of subjects: 157
Study 29797670 — intervention group
Group type: COMPARATOR
Intervention: Imiquimod 5% cream (FTF group)
Number of subjects: 157
Study 28823947 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2269557 1000 μg
Number of subjects: 64
Study 28823947 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2269557 (various doses: 100, 200, 500, 700, 1000, 2000 μg)
Number of subjects: 64
Study 28823947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 25974776 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal suction technique and ultrasonic surgery approach
Number of subjects: 30
Study 25974776 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique with rotary instruments (control)
Number of subjects: 30
Study 23633445 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 200
Study 23633445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 200
Study 20959857 — intervention group
Group type: EXPERIMENTAL
Intervention: Oolong tea
Number of subjects: 19
Study 20959857 — intervention group
Group type: EXPERIMENTAL
Intervention: Oolong tea with added catechins
Number of subjects: 19
Study 20959857 — intervention group
Group type: EXPERIMENTAL
Intervention: Oolong tea with added oolong tea polyphenols
Number of subjects: 19
Study 20959857 — intervention group
Group type: COMPARATOR
Intervention: Caffeinated water
Number of subjects: 19
Study 20959857 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented water
Number of subjects: 19
Study 17484511 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg DRSP/30 microg ethinyl estradiol (EE)
Number of subjects: 91
Study 17484511 — intervention group
Group type: COMPARATOR
Intervention: 2 mg cyproterone acetate (CPA)/35 microg EE
Number of subjects: 91
Study 15315115 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding with human milk (enteral trophic nutrition) and fortified with human milk fortifier
Number of subjects: 100
Study 15315115 — intervention group
Group type: COMPARATOR
Intervention: Control group (not fed early with human milk and not given human milk fortifier)
Number of subjects: 100
Study 11593127 — intervention group
Group type: COMPARATOR
Intervention: Infant formula (group M, n = 56)
Number of subjects: 112
Study 11593127 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt (group Y, n = 56)
Number of subjects: 112
Study 11593127 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt (group Y) in children with reducing sugars in stools
Number of subjects: 112
Study 11593127 — intervention group
Group type: COMPARATOR
Intervention: Infant formula (group M) in children with reducing sugars in stools
Number of subjects: 112
Study 9638309 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of Tramal drops (100 mg tramadol-HCl)
Number of subjects: 8
Study 9638309 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection of tramadol (100 mg tramadol-HCl)
Number of subjects: 8
Study 9638309 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of Tramal drops
Number of subjects: 8
Study 9638309 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection of tramadol
Number of subjects: 8
Study 7974587 — intervention group
Group type: EXPERIMENTAL
Intervention: CC method of measuring carotid stenosis
Number of subjects: 1001
Study 7974587 — intervention group
Group type: COMPARATOR
Intervention: ECST method of measuring carotid stenosis
Number of subjects: 1001
Study 7974587 — intervention group
Group type: COMPARATOR
Intervention: NASCET method of measuring carotid stenosis
Number of subjects: 1001
Study 2592585 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 9
Study 2592585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31038698 — intervention group
Group type: EXPERIMENTAL
Intervention: Bothersome lower urinary tract symptoms (incontinence)
Number of subjects: 23240
Study 31038698 — intervention group
Group type: EXPERIMENTAL
Intervention: Bothersome lower urinary tract symptoms (nocturia)
Number of subjects: 23240
Study 31038698 — intervention group
Group type: COMPARATOR
Intervention: Age group comparison
Number of subjects: 23240
Study 31038698 — intervention group
Group type: COMPARATOR
Intervention: Different urological symptoms
Number of subjects: 23240
Study 29951768 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute cocoa flavanols (530 mg CF, 100 mg epicatechin)
Number of subjects: 20
Study 29951768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26808137 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose/intensity regimen of behavior modification (large-group parent training)
Number of subjects: 146
Study 26808137 — intervention group
Group type: COMPARATOR
Intervention: Low dose of stimulant medication
Number of subjects: 146
Study 26808137 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity behavior modification
Number of subjects: 146
Study 25198196 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 0
Study 25198196 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib followed by ipilimumab
Number of subjects: 0
Study 25198196 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 0
Study 22784349 — intervention group
Group type: EXPERIMENTAL
Intervention: Manasamitra Vataka tablets (100 mg twice daily for 30 days)
Number of subjects: 72
Study 22784349 — intervention group
Group type: EXPERIMENTAL
Intervention: Manasamitra Vataka tablets (100 mg twice daily for 30 days) + Shirodhara (first 7 days)
Number of subjects: 72
Study 22784349 — intervention group
Group type: COMPARATOR
Intervention: Clonazepam 0.75 mg daily in divided dose for 30 days
Number of subjects: 72
Study 20409337 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream for 6 weeks (superficial basal cell carcinoma) or 12 weeks (nodular basal cell carcinoma)
Number of subjects: 500
Study 20409337 — intervention group
Group type: COMPARATOR
Intervention: Excisional surgery
Number of subjects: 500
Study 20409337 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 500
Study 17826977 — intervention group
Group type: EXPERIMENTAL
Intervention: CDE (cyclophosphamide/doxorubicin/etoposide)
Number of subjects: 203
Study 17826977 — intervention group
Group type: COMPARATOR
Intervention: CP (carboplatin/paclitaxel)
Number of subjects: 203
Study 16086364 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine HCl 120 mg
Number of subjects: 0
Study 16086364 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine HCl 30 mg
Number of subjects: 0
Study 16086364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12697867 — intervention group
Group type: COMPARATOR
Intervention: High-dose chlorambucil (15 mg/m2/d) plus prednisone (100 mg/d) for 5 days (HD-CHL-P; arm A)
Number of subjects: 170
Study 12697867 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chlorambucil (15 mg/m2/d) plus prednisone (100 mg/d) for 5 days plus epirubicin 60 mg/m2 intravenous on day 1 (arm B)
Number of subjects: 170
Study 12697867 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa (IFNalpha-2a; 3 MU, three times weekly) for 12 months
Number of subjects: 170
Study 12697867 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 170
Study 10933079 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive seminar for physicians focused on communication and teaching skills for asthma management.
Number of subjects: 637
Study 10933079 — intervention group
Group type: EXPERIMENTAL
Intervention: Children seen by treatment group physicians.
Number of subjects: 637
Study 10933079 — intervention group
Group type: COMPARATOR
Intervention: Control group physicians (not specified intervention).
Number of subjects: 637
Study 8879895 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha daily for 4 weeks and then intermittently for 20 weeks (total dose, 348 MU)
Number of subjects: 127
Study 8879895 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha daily for 2 weeks and then intermittently for 22 weeks (total dose, 480 MU)
Number of subjects: 127
Study 8879895 — intervention group
Group type: COMPARATOR
Intervention: IFN‐alpha daily for 8 weeks (total dose, 336 MU)
Number of subjects: 127
Study 1995974 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 244
Study 1995974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 6661605 — intervention group
Group type: EXPERIMENTAL
Intervention: Real ECT
Number of subjects: 62
Study 6661605 — intervention group
Group type: COMPARATOR
Intervention: Pseudo-ECT
Number of subjects: 62
Study 30768414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (CBT)
Number of subjects: 439
Study 30768414 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 439
Study 30768414 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive‐behavioral and fluoxetine treatment (COMB)
Number of subjects: 439
Study 30768414 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 439
Study 28356125 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music therapy offered three times per week in a community centre with a focus on songwriting.
Number of subjects: 30
Study 28356125 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no intervention during the study period).
Number of subjects: 30
Study 27693439 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine umbilical cord care (10 mL of a 4% chlorhexidine solution applied once per day until 3 days after cord drop)
Number of subjects: 39679
Study 27693439 — intervention group
Group type: COMPARATOR
Intervention: Dry cord care (control)
Number of subjects: 39679
Study 24118830 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (Lescol®) 40-80 mg
Number of subjects: 60
Study 24118830 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (Omacor®) high-dose (2-4 g)
Number of subjects: 60
Study 24118830 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (Omacor®) low-dose (1 g)
Number of subjects: 60
Study 24118830 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (Omacor®) low-dose + fluvastatin
Number of subjects: 60
Study 24118830 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (Omacor®) high-dose + fluvastatin
Number of subjects: 60
Study 24118830 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active drug)
Number of subjects: 60
Study 22144725 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization out of bed after 52 hours
Number of subjects: 50
Study 22144725 — intervention group
Group type: COMPARATOR
Intervention: Delayed mobilization out of bed after seven days
Number of subjects: 50
Study 19171735 — intervention group
Group type: EXPERIMENTAL
Intervention: A1C level
Number of subjects: 0
Study 17206633 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab (300 mg) plus infliximab (5 mg/kg)
Number of subjects: 79
Study 17206633 — intervention group
Group type: COMPARATOR
Intervention: Infliximab (5 mg/kg) alone
Number of subjects: 79
Study 16295704 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 332
Study 16295704 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management (SM)
Number of subjects: 332
Study 16295704 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management (SM) with adequate adherence
Number of subjects: 332
Study 12476481 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate 0.05% cream plus UVB radiation with penicillin
Number of subjects: 60
Study 12476481 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate 0.05% cream plus UVB radiation without penicillin
Number of subjects: 60
Study 12476481 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral psoralen plus ultraviolet A (PUVA) therapy
Number of subjects: 60
Study 12476481 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic retinoids therapy
Number of subjects: 60
Study 10378438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional group (informed about novel sounds and asked to memorize)
Number of subjects: 32
Study 10378438 — intervention group
Group type: COMPARATOR
Intervention: Incidental group (not informed about novel sounds)
Number of subjects: 32
Study 8527622 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine bismuth citrate
Number of subjects: 12
Study 8527622 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 1793881 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 0.3 mg/kg
Number of subjects: 30
Study 1793881 — intervention group
Group type: COMPARATOR
Intervention: thiopental 5 mg/kg
Number of subjects: 30
Study 1793881 — intervention group
Group type: COMPARATOR
Intervention: diazepam 0.4 mg/kg
Number of subjects: 30
Study 6891235 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucebral‐N (80 mg etofylline and 100 mg cyclandelate) administered for 4 weeks
Number of subjects: 0
Study 30760337 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 73
Study 30760337 — intervention group
Group type: COMPARATOR
Intervention: Standard Surgical Dressing (SSD)
Number of subjects: 73
Study 28098165 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF)
Number of subjects: 240
Study 28098165 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) and oxymetazoline (OXY)
Number of subjects: 240
Study 28098165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 28098165 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) and placebo
Number of subjects: 240
Study 28098165 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo and oxymetazoline (OXY)
Number of subjects: 240
Study 28098165 — intervention group
Group type: COMPARATOR
Intervention: Placebo and placebo
Number of subjects: 240
Study 26048168 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU+SCT
Number of subjects: 538
Study 26048168 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 538
Study 23219538 — intervention group
Group type: EXPERIMENTAL
Intervention: Epididymectomy with concurrent administration of hyaluronic acid and carboxymethylcellulose (group 1)
Number of subjects: 43
Study 23219538 — intervention group
Group type: COMPARATOR
Intervention: Epididymectomy only (group 2)
Number of subjects: 43
Study 21544020 — intervention group
Group type: EXPERIMENTAL
Intervention: P6 stimulation
Number of subjects: 134
Study 21544020 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 134
Study 18470667 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate monotherapy (5 mg/day)
Number of subjects: 48
Study 18470667 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K(2) (45 mg/day) plus alendronate (5 mg/day)
Number of subjects: 48
Study 18470667 — intervention group
Group type: COMPARATOR
Intervention: Alendronate monotherapy
Number of subjects: 48
Study 18470667 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vitamin K(2) and alendronate
Number of subjects: 48
Study 16541981 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic practice
Number of subjects: 38
Study 16541981 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor intervention
Number of subjects: 38
Study 16541981 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 12671780 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and counseling intervention (3 individual sessions by trained nurses)
Number of subjects: 244
Study 12671780 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard of care)
Number of subjects: 244
Study 12671780 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and counseling intervention
Number of subjects: 244
Study 11093992 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 microg x kg.min(‐1) at induction, then 0.2 microg x kg x min(‐1))
Number of subjects: 34
Study 11093992 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (3 microg/kg)
Number of subjects: 34
Study 9368164 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐0 nylon suture
Number of subjects: 100
Study 9368164 — intervention group
Group type: COMPARATOR
Intervention: 9‐0 nylon suture
Number of subjects: 100
Study 1403077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250mg every 12 hours for 10 days
Number of subjects: 55
Study 1403077 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 50mg/kg/day in three divided doses for 10 days
Number of subjects: 55
Study 3896885 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine (30 mg/D)
Number of subjects: 16
Study 3896885 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 31908254 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus followed by 1.5 mg/kg/h infusion until 2 h after surgery)
Number of subjects: 60
Study 31908254 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with 0.9% saline (equal volume to lidocaine group)
Number of subjects: 60
Study 31908254 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 60
Study 28958701 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (HD) influenza vaccine
Number of subjects: 106
Study 28958701 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (SD) influenza vaccine
Number of subjects: 106
Study 28958701 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza infection post-vaccination
Number of subjects: 106
Study 28958701 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus (CMV) seropositivity
Number of subjects: 106
Study 27322715 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP/SMX) during high-dose methotrexate (HDMTX)
Number of subjects: 424
Study 27322715 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP/SMX) during low-dose methotrexate (40 mg/m)
Number of subjects: 424
Study 24708676 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive day-camp intervention (6-week multi-component day camp including increased physical activity, healthy diet, and health education) followed by 46 weeks of family-based habitual intervention.
Number of subjects: 115
Study 24708676 — intervention group
Group type: COMPARATOR
Intervention: Standard care arm (two weekly hours of physical activity training for six weeks).
Number of subjects: 115
Study 23218157 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive ziprasidone 60-80 mg
Number of subjects: 680
Study 23218157 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive ziprasidone 20-40 mg
Number of subjects: 680
Study 23218157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 680
Study 20932302 — intervention group
Group type: COMPARATOR
Intervention: Video podcast
Number of subjects: 100
Study 20932302 — intervention group
Group type: EXPERIMENTAL
Intervention: Live lecture
Number of subjects: 100
Study 20932302 — intervention group
Group type: COMPARATOR
Intervention: Multiple choice questions
Number of subjects: 100
Study 18418571 — intervention group
Group type: EXPERIMENTAL
Intervention: SSD-coated ETT (SSD-ETT, n=23)
Number of subjects: 46
Study 18418571 — intervention group
Group type: COMPARATOR
Intervention: Standard non-coated ETT (St-ETT, n=23; control group)
Number of subjects: 46